{"gene":"MGMT","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":2007,"finding":"MGMT is a suicide enzyme (alkyltransferase) that repairs O6-alkylguanine DNA lesions by irreversibly transferring the alkyl group from the O6 position of guanine to a cysteine residue in its own active site (Cys145), thereby becoming inactivated in the process. It also repairs larger adducts at the O6-position such as O6-chloroethylguanine.","method":"In vitro biochemical assays, active-site characterization, review of mechanistic studies","journal":"DNA repair","confidence":"High","confidence_rationale":"Tier 1 / Strong — catalytic mechanism (suicide alkyltransferase, active-site Cys) established by multiple independent biochemical studies and replicated across labs over decades","pmids":["17485253","11981013","17482889"],"is_preprint":false},{"year":2007,"finding":"O6-methylguanine (O6-MeG) induced by MGMT-repaired lesions causes cell death and clastogenicity via a mechanism that requires MutS-alpha-dependent mismatch repair (MMR), whereas O6-chloroethylguanine-induced killing occurs independently of MMR. Extensive DNA replication is required for O6-MeG to provoke cytotoxicity, and the secondary DNA double-strand breaks trigger apoptosis via ATM/ATR, Chk1, Chk2, p53, and p73.","method":"Genetic epistasis using MGMT-modulated and MMR-deficient cell systems; apoptosis pathway analysis","journal":"DNA repair","confidence":"High","confidence_rationale":"Tier 2 / Strong — epistasis experiments across multiple cell lines, replicated across labs, mechanistic pathway placement established","pmids":["17485253","11554312"],"is_preprint":false},{"year":2001,"finding":"In MGMT-deficient cells, O6-methylguanine is the major genotoxic, recombinogenic, and apoptotic lesion; its cytotoxicity requires mismatch repair. In cells with high MGMT expression or low O6-methylguanine formation, N-alkylation lesions repaired by base excision repair (BER) become the dominant genotoxic lesions.","method":"Genetic modulation (transfection, mutational inactivation) of MGMT and BER components; cell survival assays","journal":"Progress in nucleic acid research and molecular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function and gain-of-function experiments across multiple DNA repair pathways with defined phenotypic readouts, replicated","pmids":["11554312"],"is_preprint":false},{"year":2005,"finding":"Epigenetic silencing of MGMT by promoter CpG island methylation suppresses MGMT expression in glioblastoma, and this silencing predicts benefit from temozolomide chemotherapy. Promoter methylation was confirmed as the key mechanism of MGMT gene silencing.","method":"Methylation-specific PCR of tumor tissue from a randomized clinical trial; correlation with survival outcomes","journal":"The New England journal of medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — prospective randomized trial with molecular assay, independently replicated across multiple cohorts","pmids":["15758010"],"is_preprint":false},{"year":2005,"finding":"Dimethylation of histone H3 lysine 9 and binding of methyl-CpG binding proteins are common and essential epigenetic marks in MGMT-silenced cancer cells, and MGMT silencing can occur without DNA hypermethylation in some cancer cells.","method":"Chromatin immunoprecipitation and analysis of histone modifications in MGMT-silenced cell lines","journal":"Biochemistry and cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — chromatin analysis in silenced cells, single lab, limited orthogonal validation reported in abstract","pmids":["16094446"],"is_preprint":false},{"year":2010,"finding":"In MGMT-methylated glioblastoma, MGMT promoter methylation correlates with a non-permissive chromatin status, very low MGMT transcript levels, and undetectable MGMT enzymatic activity, demonstrating functional linkage between epigenetic silencing and loss of repair capacity.","method":"Chromatin status analysis, real-time PCR for MGMT transcript, MGMT activity assay in paired glioblastoma and glioblastoma-derived sphere samples","journal":"Clinical cancer research","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — multiple orthogonal methods (chromatin, RNA, enzymatic activity) in same study, single lab","pmids":["21097691"],"is_preprint":false},{"year":2013,"finding":"NDRG1 (an mTOR target induced by hypoxia, irradiation, corticosteroids, and chronic alkylating agent exposure) binds and stabilizes MGMT protein, thereby conferring MGMT-dependent resistance to alkylating chemotherapy in glioblastoma.","method":"Co-immunoprecipitation, Western blot, NDRG1 knockdown/overexpression, in vivo tumor models","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP demonstrating NDRG1-MGMT complex, functional rescue experiments, in vivo validation","pmids":["24367102"],"is_preprint":false},{"year":2019,"finding":"In MGMT-deficient tumor cells, temozolomide activates the ATR-Chk1 signaling axis (inducing DNA double-strand breaks and G2-M arrest leading to ATR-dependent Chk1 phosphorylation) in an MGMT-status-dependent manner, and this sensitizes MGMT-deficient cells to ATR inhibitors both in vitro and in vivo.","method":"Cell viability assays, DNA damage markers (γ-H2AX), cell cycle analysis, ATR inhibitor combination in vitro and in vivo across multiple tumor cell types","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods, multiple cell types, in vivo confirmation, mechanistic pathway (MGMT→ATR-Chk1) established","pmids":["31273061"],"is_preprint":false},{"year":2022,"finding":"PARP1 and MGMT interact directly in a DNA-independent manner; upon DNA damage, PARP1 PARylates MGMT, and this PARylation enhances O6-methylguanine repair, revealing functional crosstalk between BER (PARP1) and MGMT-mediated direct reversal repair pathways.","method":"Co-immunoprecipitation, in vitro PARylation assay, DNA damage-inducible complex formation, chromatin binding assays","journal":"Journal of hematology & oncology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — direct protein interaction demonstrated by Co-IP and in vitro PARylation assay with functional readout (enhanced O6meG repair), multiple orthogonal methods","pmids":["36242092"],"is_preprint":false},{"year":2016,"finding":"Post-translational modifications of MGMT including ubiquitination, sumoylation, and glutathionylation affect MGMT protein stability and DNA repair activity. The active site Cys145 can be targeted by thiol-reacting compounds (e.g., disulfiram, dithiocarbamates) to inactivate and deplete MGMT.","method":"Biochemical assays of PTM effects on MGMT stability and activity; active-site mutagenesis and chemical inhibition studies","journal":"Mini reviews in medicinal chemistry","confidence":"Medium","confidence_rationale":"Tier 1-2 / Weak — PTM effects reviewed from experimental data but described in a review/mini-review context; individual experiments from multiple labs","pmids":["26202203"],"is_preprint":false},{"year":2019,"finding":"MGMT activates DUB3 transcription, and the resulting MGMT-DUB3-MCL1 axis promotes chemoresistance in ovarian cancer: DUB3 interacts with and deubiquitinates MCL1 in the cytoplasm, protecting MCL1 from proteasomal degradation.","method":"Co-immunoprecipitation (DUB3-MCL1 interaction), transcriptional reporter assays (MGMT activating DUB3), in vitro and in vivo functional studies with MGMT inhibitor PaTrin-2","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP for DUB3-MCL1 interaction, transcriptional activation of DUB3 by MGMT, in vivo validation, single lab","pmids":["30718431"],"is_preprint":false},{"year":2018,"finding":"An enhancer located between the MKI67 and MGMT gene promoters is activated in temozolomide-resistant glioblastoma; forced activation of this enhancer increases MGMT expression, and CRISPR/Cas9-mediated deletion of the enhancer reduces MGMT expression and restores temozolomide sensitivity.","method":"CRISPR/Cas9 enhancer deletion and activation, gene expression analysis, TMZ sensitivity assays in patient-derived xenograft lines and recurrent tumor samples","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — CRISPR gain- and loss-of-function at defined genomic locus with functional readout (MGMT expression and TMZ sensitivity), PDX models","pmids":["30054476"],"is_preprint":false},{"year":2019,"finding":"NF-κB signaling regulates MGMT expression: NF-κB inhibition by MG-132 decreases MGMT expression in glioma stem-like cells and enhances temozolomide sensitivity in MGMT-positive GSCs.","method":"NF-κB inhibitor (MG-132) treatment, Western blot for MGMT, cell viability/IC50 assays in glioma stem-like cells","journal":"Chinese journal of cancer","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single inhibitor experiment, indirect pathway modulation, single lab, no direct promoter binding demonstrated","pmids":["23958055"],"is_preprint":false},{"year":2017,"finding":"Hedgehog/Gli1 signaling pathway regulates MGMT expression independently of MGMT promoter methylation. Gli1 binds a site at -411 to -403 bp upstream of the MGMT transcriptional start site, and activation or inhibition of Gli1 increases or decreases MGMT expression and TMZ resistance respectively.","method":"Chromatin immunoprecipitation identifying Gli1 binding site in MGMT promoter, Gli1 overexpression/inhibition (cyclopamine), methylation-specific PCR, in vivo xenograft model","journal":"Cancer cell international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP identifies direct Gli1 binding at MGMT promoter, functional gain/loss-of-function with in vivo validation, single lab","pmids":["29225516"],"is_preprint":false},{"year":2018,"finding":"Fstl1 regulates MGMT expression via the DIP2A/HDAC2-DMAP1 axis: DIP2A cooperates with the HDAC2-DMAP1 complex to enhance H3K9Ac deacetylation at the MGMT promoter and suppress MGMT transcription. Fstl1 competitively binds DIP2A to block its nuclear translocation, preventing DIP2A from binding the HDAC2-DMAP1 complex and resulting in increased H3K9Ac and MGMT expression.","method":"Co-immunoprecipitation (Fstl1-DIP2A, DIP2A-HDAC2-DMAP1), nuclear fractionation, ChIP (H3K9Ac at MGMT promoter), knockdown/overexpression, in vivo and in vitro TMZ resistance assays","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, ChIP showing histone modification at MGMT promoter, DIP2A rescue experiment, in vivo validation, single lab with multiple orthogonal methods","pmids":["30542120"],"is_preprint":false},{"year":2019,"finding":"HDAC8 regulates MGMT protein levels via interaction with the proteasome receptor ADRM1. HDAC8 inhibition decreases MGMT protein levels in glioblastoma cell lines independently of MGMT promoter methylation status; this interaction between HDAC8 and ADRM1 is disrupted by temozolomide exclusively in TMZ-sensitive cells.","method":"HDAC8-specific inhibitor and shRNA knockdown, ADRM1 interaction studies (Co-IP), Western blot for MGMT, cell viability assays","journal":"Genes & cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP for HDAC8-ADRM1 interaction, shRNA and pharmacological inhibition with functional MGMT readout, single lab","pmids":["31798765"],"is_preprint":false},{"year":2022,"finding":"BET protein inhibition (BETi) reduces MGMT expression in glioblastoma cells by reducing BRD4 and RNA polymerase II binding at the MGMT promoter. BETi also inhibits temozolomide-induced MGMT upregulation; ectopic MGMT expression under an unrelated promoter is unaffected by BETi, confirming the mechanism is transcriptional and promoter-specific.","method":"ChIP for BRD4 and Pol II at MGMT promoter, ectopic MGMT overexpression controls, γ-H2AX assay, BETi treatment in glioblastoma-derived spheres","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrating BRD4/Pol II at MGMT promoter, mechanistic rescue experiment with ectopic MGMT, multiple orthogonal methods, single lab","pmids":["36513631"],"is_preprint":false},{"year":2020,"finding":"MGMT genomic rearrangements (structural variants) in recurrent gliomas lead to MGMT overexpression independently of promoter methylation changes; CRISPR/Cas9-generated MGMT rearrangements in glioma cells confer temozolomide resistance both in vitro and in vivo.","method":"CRISPR/Cas9-mediated genomic rearrangements, gene expression analysis, in vitro and in vivo TMZ resistance assays, exosome detection of fusion transcripts","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — CRISPR-generated structural variants with functional TMZ resistance readout in vitro and in vivo, single lab with multiple orthogonal methods","pmids":["32753598"],"is_preprint":false},{"year":2014,"finding":"Gene body cytosine modifications in the MGMT locus positively regulate MGMT expression independently of promoter methylation; inducing gene body hypomethylation with decitabine decreases MGMT expression in glioblastoma and lymphoblastoid cell lines and sensitizes resistant cells to temozolomide.","method":"Methylation analysis of 91 glioblastoma samples, decitabine treatment with MGMT expression measurement, TMZ sensitivity assays","journal":"Molecular cancer therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional intervention (decitabine) with MGMT expression and drug sensitivity readout, supported by human tumor data; single lab","pmids":["24568970"],"is_preprint":false},{"year":2020,"finding":"MGMT suppresses ATG4B expression in gastric cancer cells, thereby inhibiting autophagy; cisplatin inhibits MGMT, which leads to ATG4B upregulation, increased autophagy, and decreased chemosensitivity. MGMT inhibition-mediated ATG4B derepression drives autophagy-dependent DDP resistance.","method":"MGMT knockdown/inhibition, ATG4B expression analysis, autophagy assays, in vivo xenograft model with chloroquine combination","journal":"Biomedicine & pharmacotherapy","confidence":"Low","confidence_rationale":"Tier 3 / Weak — indirect regulation of ATG4B by MGMT, mechanistic link inferred from inhibitor studies; single lab, limited mechanistic detail in abstract","pmids":["32007918"],"is_preprint":false},{"year":2024,"finding":"In MGMT-methylated glioblastoma cells, temozolomide activates CHK1, which phosphorylates the RNA helicase DDX46, inducing a dense-to-loose conformational change that increases DDX46 helicase activity. DDX46-mediated structural remodeling of lncRNA LINC01956 exposes binding motifs that interact with the 3'UTR of MGMT mRNA, promoting nuclear export and increased MGMT protein abundance, thus driving TMZ resistance.","method":"RNA immunoprecipitation (RIP), CLIP, structural analysis, mRNA export assays, PDX and tumor organoid models, CHK1 inhibitor rescue experiments","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (RIP, structural remodeling, mRNA export), mechanistic rescue with CHK1 inhibitor, PDX and organoid models, single lab","pmids":["39356744"],"is_preprint":false},{"year":2024,"finding":"MGMT expression and promoter methylation exhibit intrinsic circadian rhythms in glioblastoma cells; MGMT activity is lowest at the daily peak of Bmal1 transcription, and TMZ sensitivity correspondingly peaks at this time. Inhibition of MGMT activity with O6-benzylguanine abolishes the daily rhythm in TMZ sensitivity.","method":"Real-time bioluminescence reporters for circadian clock genes and MGMT, MGMT transcript and methylation time-course analysis, TMZ viability assays at different circadian times, in vivo xenograft morning vs. evening TMZ delivery","journal":"Journal of neuro-oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (reporter, transcript, methylation, functional TMZ rescue with O6-BG), in vivo confirmation, single lab","pmids":["38277015"],"is_preprint":false},{"year":2015,"finding":"MGMT-positive cancer cells show strong dependence on PARP for survival under temozolomide treatment; in vitro and in vivo, MGMT-positive (but not MGMT-deficient) cells are highly sensitive to the combination of temozolomide and PARP inhibitors, with MGMT-positive melanoma cells undergoing enhanced senescence.","method":"In vitro cell viability assays, in vivo tumor models, PARP inhibitor combination studies stratified by MGMT expression","journal":"Molecular cancer therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo combination studies with MGMT-stratified cells, single lab","pmids":["25777962"],"is_preprint":false},{"year":2007,"finding":"MGMT polymorphic variants Leu84Phe, Ile143Val, and Lys178Arg have subtle effects on alkyltransferase activity; studies in cells show these variants do not dramatically alter repair function. The proposed role of alkylated MGMT in modifying Estrogen Receptor alpha activity was not confirmed as a major function in experimental studies.","method":"Alkyltransferase activity assays of polymorphic variants, ER-alpha transcriptional reporter assays","journal":"DNA repair","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro enzymatic activity measurement of variants plus negative result for ER-alpha modulation; single lab","pmids":["17569599"],"is_preprint":false},{"year":2012,"finding":"A high-throughput MGMT activity assay was developed based on the mechanism whereby MGMT irreversibly transfers the alkyl group from O6-position guanine to its active site cysteine; biotin-tagged O6-benzylguanine (a substrate analog) is transferred to MGMT, forming a MGMT-BG-biotin complex that can be captured on anti-MGMT-coated plates and quantified.","method":"Biochemical assay development using MGMT's suicide mechanism; validation in cell extracts with streptavidin-alkaline phosphatase detection","journal":"Mutation research","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro biochemical assay exploiting catalytic mechanism, validated across samples; assay development paper","pmids":["22609488"],"is_preprint":false},{"year":2019,"finding":"IKBKE enhances temozolomide resistance in glioblastoma cells by activating the AKT/NF-κB signaling pathway, which upregulates MGMT expression; IKBKE knockdown reduces MGMT levels and sensitizes cells to TMZ in vitro and in vivo.","method":"IKBKE knockdown/overexpression, Western blot for MGMT and AKT/NF-κB pathway components, cell proliferation and apoptosis assays, in vivo intracranial xenograft model","journal":"Clinical & translational oncology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pathway inhibition with MGMT readout, indirect regulation via AKT/NF-κB, single lab, no direct promoter binding shown","pmids":["31865606"],"is_preprint":false}],"current_model":"MGMT is a suicide DNA repair alkyltransferase that directly removes alkyl adducts (principally O6-methylguanine) from DNA by irreversible transfer to its active-site Cys145, causing self-inactivation; unrepaired O6-MeG triggers MMR-dependent DNA double-strand breaks activating the ATM/ATR→Chk1/Chk2→p53/p73 apoptotic cascade, while MGMT expression is regulated at multiple levels including promoter CpG methylation (linked to non-permissive chromatin marked by H3K9 dimethylation and reduced BRD4/Pol II occupancy), transcriptional control by Gli1 and NF-κB, an intergenic enhancer, post-translational stabilization by NDRG1 and HDAC8/ADRM1, PARylation by PARP1 (which enhances O6-MeG repair), and post-transcriptional nuclear export via CHK1-phospho-DDX46-remodeled LINC01956; additionally, MGMT activates the DUB3–MCL1 anti-apoptotic axis in a non-canonical function."},"narrative":{"mechanistic_narrative":"MGMT is a suicide DNA repair alkyltransferase that directly reverses alkylation damage by irreversibly transferring the alkyl group from the O6 position of guanine to its own active-site cysteine (Cys145), inactivating itself in the process and also handling larger O6 adducts such as O6-chloroethylguanine [PMID:17485253, PMID:11981013, PMID:17482889]. Its central biological importance lies in determining cytotoxic outcome of alkylating agents: unrepaired O6-methylguanine is the dominant genotoxic, recombinogenic and apoptotic lesion, and its killing requires MutS-alpha-dependent mismatch repair and extensive replication, generating secondary double-strand breaks that activate an ATM/ATR→Chk1/Chk2→p53/p73 apoptotic cascade [PMID:17485253, PMID:11554312]. This mechanism makes MGMT status the principal determinant of temozolomide response, and epigenetic silencing of MGMT by promoter CpG-island methylation—linked to a non-permissive chromatin state and loss of transcript and enzymatic activity—predicts clinical benefit from temozolomide in glioblastoma [PMID:15758010, PMID:21097691]. MGMT abundance is controlled at multiple additional layers: transcriptionally through a Gli1 binding site, an intergenic MKI67–MGMT enhancer, BRD4/Pol II occupancy, and HDAC2–DMAP1–mediated histone deacetylation antagonized by Fstl1–DIP2A [PMID:29225516, PMID:30054476, PMID:36513631, PMID:30542120]; through gene-body cytosine modification and genomic rearrangements that drive overexpression independent of promoter methylation [PMID:24568970, PMID:32753598]; and post-translationally via NDRG1 binding and stabilization and HDAC8–ADRM1 control of protein turnover [PMID:24367102, PMID:31798765]. MGMT also engages in functional crosstalk with base-excision repair through direct DNA-independent interaction with PARP1, which PARylates MGMT to enhance O6-methylguanine repair [PMID:36242092]. Beyond repair, MGMT exerts a non-canonical pro-survival role by transcriptionally activating DUB3 to stabilize the anti-apoptotic protein MCL1, promoting chemoresistance [PMID:30718431], and a CHK1–DDX46–LINC01956 axis remodels MGMT mRNA to promote its nuclear export and protein accumulation under temozolomide stress [PMID:39356744].","teleology":[{"year":2007,"claim":"Established the core catalytic mechanism: how MGMT removes mutagenic O6-alkyl lesions, defining it as a single-turnover suicide enzyme.","evidence":"In vitro biochemical and active-site characterization showing irreversible alkyl transfer to Cys145","pmids":["17485253","11981013","17482889"],"confidence":"High","gaps":["Does not address how spent MGMT is degraded or recycled in vivo","No structural detail on substrate selectivity for larger adducts"]},{"year":2007,"claim":"Resolved why MGMT loss is cytotoxic by placing unrepaired O6-methylguanine downstream of mismatch repair and within an ATM/ATR→Chk→p53/p73 apoptotic cascade.","evidence":"Genetic epistasis in MGMT-modulated and MMR-deficient cells with apoptosis pathway analysis","pmids":["17485253","11554312"],"confidence":"High","gaps":["Exact molecular trigger converting O6-MeG mispairs to double-strand breaks not fully defined","Relative contribution of p53 vs p73 unresolved"]},{"year":2001,"claim":"Defined the lesion hierarchy dictated by MGMT level, showing O6-MeG dominates genotoxicity in MGMT-deficient cells while BER-repaired N-alkylations dominate when MGMT is high.","evidence":"Gain/loss-of-function modulation of MGMT and BER components with survival readouts","pmids":["11554312"],"confidence":"High","gaps":["Quantitative thresholds of MGMT activity setting the switch not established"]},{"year":2005,"claim":"Connected MGMT promoter CpG methylation to gene silencing and to clinical temozolomide benefit, making MGMT status a predictive biomarker.","evidence":"Methylation-specific PCR on randomized-trial glioblastoma tissue correlated with survival","pmids":["15758010"],"confidence":"High","gaps":["Does not explain methylation-independent silencing or reactivation","Assay does not measure enzymatic activity directly"]},{"year":2010,"claim":"Confirmed that promoter methylation translates into functional loss by linking non-permissive chromatin to undetectable transcript and enzymatic activity.","evidence":"Chromatin, RT-PCR and activity assays in paired glioblastoma and sphere samples; H3K9 dimethylation and methyl-CpG binding marks defined in silenced cells","pmids":["21097691","16094446"],"confidence":"High","gaps":["Mechanism establishing the silenced chromatin state not defined","Methylation-independent silencing in some cells unexplained"]},{"year":2013,"claim":"Identified post-translational stabilization as a resistance mechanism, showing NDRG1 binds and stabilizes MGMT protein independent of transcription.","evidence":"Reciprocal Co-IP, knockdown/overexpression and in vivo tumor models","pmids":["24367102"],"confidence":"High","gaps":["Structural basis of NDRG1-MGMT binding unknown","Whether NDRG1 blocks specific degradation pathway not defined"]},{"year":2017,"claim":"Revealed methylation-independent transcriptional control by mapping a direct Gli1 binding site upstream of the MGMT start site.","evidence":"ChIP, Gli1 gain/loss-of-function and xenograft validation","pmids":["29225516"],"confidence":"Medium","gaps":["Single lab; cooperating transcription factors at the promoter not mapped"]},{"year":2018,"claim":"Demonstrated distal and chromatin-level transcriptional regulation through an intergenic MKI67-MGMT enhancer and Fstl1-DIP2A-controlled histone acetylation.","evidence":"CRISPR enhancer deletion/activation and reciprocal Co-IP/ChIP for the Fstl1-DIP2A-HDAC2-DMAP1 axis in PDX and resistant models","pmids":["30054476","30542120"],"confidence":"High","gaps":["Interplay between enhancer activity and promoter methylation not resolved","Upstream signals controlling Fstl1/DIP2A nuclear shuttling unclear"]},{"year":2014,"claim":"Showed gene-body methylation positively regulates MGMT, distinguishing it from repressive promoter methylation and providing a decitabine-sensitive node.","evidence":"Methylation profiling of 91 tumors plus decitabine intervention with expression and TMZ readouts","pmids":["24568970"],"confidence":"Medium","gaps":["Reader/effector linking gene-body methylation to transcription not identified"]},{"year":2019,"claim":"Uncovered a CHK1-engaging therapeutic vulnerability and a non-canonical pro-survival output, with MGMT-deficient cells sensitized to ATR inhibition and MGMT activating a DUB3-MCL1 anti-apoptotic axis.","evidence":"ATR/Chk1 damage and inhibitor combination studies; Co-IP and transcriptional reporter assays for the MGMT-DUB3-MCL1 axis with in vivo validation","pmids":["31273061","30718431"],"confidence":"High","gaps":["How MGMT transcriptionally activates DUB3 mechanistically undefined","DUB3-MCL1 axis tested mainly in ovarian cancer context"]},{"year":2019,"claim":"Extended protein-level control by linking HDAC8-ADRM1 to MGMT turnover, providing a methylation-independent way to deplete MGMT pharmacologically.","evidence":"HDAC8 inhibition/shRNA and HDAC8-ADRM1 Co-IP with MGMT and viability readouts","pmids":["31798765"],"confidence":"Medium","gaps":["Single lab; whether HDAC8 acts via deacetylation or scaffolding of ADRM1 unresolved"]},{"year":2022,"claim":"Established direct repair-pathway crosstalk by demonstrating PARP1 binds and PARylates MGMT to enhance O6-MeG repair, and that MGMT-positive cells depend on PARP under temozolomide.","evidence":"Co-IP, in vitro PARylation and chromatin-binding assays; MGMT-stratified PARP inhibitor combination studies in vitro and in vivo","pmids":["36242092","25777962"],"confidence":"High","gaps":["PARylation site(s) on MGMT and effect on its suicide mechanism not mapped"]},{"year":2024,"claim":"Defined post-transcriptional and chronobiological control of MGMT, with a CHK1-DDX46-LINC01956 axis driving MGMT mRNA export and intrinsic circadian rhythms in MGMT activity dictating temozolomide timing sensitivity.","evidence":"RIP/CLIP, mRNA export assays and CHK1 inhibitor rescue in PDX/organoids; circadian bioluminescence reporters with timed TMZ dosing and O6-benzylguanine rescue","pmids":["39356744","38277015"],"confidence":"High","gaps":["Generality of the LINC01956 mechanism beyond methylated glioblastoma untested","Clock components directly driving MGMT promoter rhythmicity not identified"]},{"year":null,"claim":"How the diverse transcriptional, post-transcriptional and post-translational regulators of MGMT are integrated into a unified control logic, and whether MGMT's non-repair functions are broadly operative, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of regulated MGMT complexes","Cross-regulation among NDRG1, PARP1, HDAC8 and the LINC01956 axis untested","Physiological (non-cancer) role of MGMT regulation undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140097","term_label":"catalytic activity, acting on DNA","supporting_discovery_ids":[0,24]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,8]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[10]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[20]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[10]}],"pathway":[{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[0,1,8]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,17]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[1,10]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[13,16,14]}],"complexes":[],"partners":["NDRG1","PARP1","ADRM1","DDX46"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P16455","full_name":"Methylated-DNA--protein-cysteine methyltransferase","aliases":["6-O-methylguanine-DNA methyltransferase","MGMT","O-6-methylguanine-DNA-alkyltransferase"],"length_aa":207,"mass_kda":21.6,"function":"Involved in the cellular defense against the biological effects of O6-methylguanine (O6-MeG) and O4-methylthymine (O4-MeT) in DNA. Repairs the methylated nucleobase in DNA by stoichiometrically transferring the methyl group to a cysteine residue in the enzyme. This is a suicide reaction: the enzyme is irreversibly inactivated","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P16455/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MGMT","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MGMT","total_profiled":1310},"omim":[{"mim_id":"615826","title":"SPERM-TAIL PG-RICH REPEAT-CONTAINING PROTEIN 1; STPG1","url":"https://www.omim.org/entry/615826"},{"mim_id":"609941","title":"DEAFNESS, AUTOSOMAL RECESSIVE 51; DFNB51","url":"https://www.omim.org/entry/609941"},{"mim_id":"300329","title":"ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 33; ZBTB33","url":"https://www.omim.org/entry/300329"},{"mim_id":"156569","title":"METHYLGUANINE-DNA METHYLTRANSFERASE; MGMT","url":"https://www.omim.org/entry/156569"},{"mim_id":"137800","title":"GLIOMA SUSCEPTIBILITY 1; GLM1","url":"https://www.omim.org/entry/137800"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"liver","ntpm":125.9}],"url":"https://www.proteinatlas.org/search/MGMT"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P16455","domains":[{"cath_id":"3.30.160.70","chopping":"2-86","consensus_level":"medium","plddt":88.0181,"start":2,"end":86},{"cath_id":"1.10.10.10","chopping":"88-183","consensus_level":"medium","plddt":94.8295,"start":88,"end":183}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P16455","model_url":"https://alphafold.ebi.ac.uk/files/AF-P16455-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P16455-F1-predicted_aligned_error_v6.png","plddt_mean":85.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MGMT","jax_strain_url":"https://www.jax.org/strain/search?query=MGMT"},"sequence":{"accession":"P16455","fasta_url":"https://rest.uniprot.org/uniprotkb/P16455.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P16455/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P16455"}},"corpus_meta":[{"pmid":"15758010","id":"PMC_15758010","title":"MGMT gene silencing and benefit from temozolomide in glioblastoma.","date":"2005","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15758010","citation_count":5719,"is_preprint":false},{"pmid":"18757334","id":"PMC_18757334","title":"Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.","date":"2008","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18757334","citation_count":681,"is_preprint":false},{"pmid":"19997073","id":"PMC_19997073","title":"MGMT promoter methylation in malignant gliomas: ready for personalized medicine?","date":"2009","source":"Nature reviews. Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/19997073","citation_count":603,"is_preprint":false},{"pmid":"17485253","id":"PMC_17485253","title":"MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents.","date":"2007","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/17485253","citation_count":506,"is_preprint":false},{"pmid":"24912512","id":"PMC_24912512","title":"MGMT testing--the challenges for biomarker-based glioma treatment.","date":"2014","source":"Nature reviews. Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/24912512","citation_count":432,"is_preprint":false},{"pmid":"16174854","id":"PMC_16174854","title":"MGMT promoter methylation and field defect in sporadic colorectal cancer.","date":"2005","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/16174854","citation_count":390,"is_preprint":false},{"pmid":"11981013","id":"PMC_11981013","title":"Clinical relevance of MGMT in the treatment of cancer.","date":"2002","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/11981013","citation_count":362,"is_preprint":false},{"pmid":"32348734","id":"PMC_32348734","title":"MGMT Status as a Clinical Biomarker in Glioblastoma.","date":"2020","source":"Trends in cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32348734","citation_count":257,"is_preprint":false},{"pmid":"15455350","id":"PMC_15455350","title":"Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors.","date":"2005","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15455350","citation_count":234,"is_preprint":false},{"pmid":"30054476","id":"PMC_30054476","title":"A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30054476","citation_count":211,"is_preprint":false},{"pmid":"32010632","id":"PMC_32010632","title":"O6-Methylguanine-DNA Methyltransferase (MGMT): Challenges and New Opportunities in Glioma Chemotherapy.","date":"2020","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32010632","citation_count":205,"is_preprint":false},{"pmid":"16428468","id":"PMC_16428468","title":"Targeted modulation of MGMT: clinical implications.","date":"2006","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/16428468","citation_count":195,"is_preprint":false},{"pmid":"21745538","id":"PMC_21745538","title":"O(6)-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: enzyme activity, promoter methylation and immunohistochemistry.","date":"2011","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/21745538","citation_count":193,"is_preprint":false},{"pmid":"26447477","id":"PMC_26447477","title":"Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26447477","citation_count":156,"is_preprint":false},{"pmid":"32753598","id":"PMC_32753598","title":"MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32753598","citation_count":154,"is_preprint":false},{"pmid":"24367102","id":"PMC_24367102","title":"mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24367102","citation_count":154,"is_preprint":false},{"pmid":"26503470","id":"PMC_26503470","title":"IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26503470","citation_count":125,"is_preprint":false},{"pmid":"24109190","id":"PMC_24109190","title":"Personalized treatment strategies in glioblastoma: MGMT promoter methylation status.","date":"2013","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/24109190","citation_count":123,"is_preprint":false},{"pmid":"21365007","id":"PMC_21365007","title":"O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21365007","citation_count":99,"is_preprint":false},{"pmid":"18091318","id":"PMC_18091318","title":"MGMT immunohistochemical expression and promoter methylation in human glioblastoma.","date":"2008","source":"Applied immunohistochemistry & molecular morphology : AIMM","url":"https://pubmed.ncbi.nlm.nih.gov/18091318","citation_count":96,"is_preprint":false},{"pmid":"18997474","id":"PMC_18997474","title":"Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study.","date":"2008","source":"Neuroepidemiology","url":"https://pubmed.ncbi.nlm.nih.gov/18997474","citation_count":93,"is_preprint":false},{"pmid":"27353036","id":"PMC_27353036","title":"MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors.","date":"2016","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27353036","citation_count":92,"is_preprint":false},{"pmid":"11554312","id":"PMC_11554312","title":"BER, MGMT, and MMR in defense against alkylation-induced genotoxicity and apoptosis.","date":"2001","source":"Progress in nucleic acid research and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11554312","citation_count":80,"is_preprint":false},{"pmid":"20179017","id":"PMC_20179017","title":"MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.","date":"2010","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20179017","citation_count":75,"is_preprint":false},{"pmid":"30718431","id":"PMC_30718431","title":"MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/30718431","citation_count":71,"is_preprint":false},{"pmid":"16094446","id":"PMC_16094446","title":"Epigenetic silencing of the MGMT gene in cancer.","date":"2005","source":"Biochemistry and cell biology = Biochimie et biologie cellulaire","url":"https://pubmed.ncbi.nlm.nih.gov/16094446","citation_count":71,"is_preprint":false},{"pmid":"23958055","id":"PMC_23958055","title":"Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells.","date":"2013","source":"Chinese journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23958055","citation_count":70,"is_preprint":false},{"pmid":"21097691","id":"PMC_21097691","title":"Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres.","date":"2010","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/21097691","citation_count":67,"is_preprint":false},{"pmid":"22214427","id":"PMC_22214427","title":"Volumetric and MGMT parameters in glioblastoma patients: survival analysis.","date":"2012","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22214427","citation_count":65,"is_preprint":false},{"pmid":"20725792","id":"PMC_20725792","title":"MGMT promoter methylation in malignant gliomas.","date":"2010","source":"Targeted oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20725792","citation_count":62,"is_preprint":false},{"pmid":"16777483","id":"PMC_16777483","title":"Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy.","date":"2006","source":"Current opinion in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16777483","citation_count":62,"is_preprint":false},{"pmid":"17898525","id":"PMC_17898525","title":"DNA repair polymorphisms XRCC1 and MGMT and risk of adult gliomas.","date":"2007","source":"Neuroepidemiology","url":"https://pubmed.ncbi.nlm.nih.gov/17898525","citation_count":60,"is_preprint":false},{"pmid":"18386788","id":"PMC_18386788","title":"Polymorphisms in MGMT and DNA repair genes and the risk of esophageal adenocarcinoma.","date":"2008","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/18386788","citation_count":57,"is_preprint":false},{"pmid":"31273061","id":"PMC_31273061","title":"Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors.","date":"2019","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/31273061","citation_count":52,"is_preprint":false},{"pmid":"31766430","id":"PMC_31766430","title":"Changes of O6-Methylguanine DNA Methyltransferase (MGMT) Promoter Methylation in Glioblastoma Relapse-A Meta-Analysis Type Literature Review.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31766430","citation_count":52,"is_preprint":false},{"pmid":"36272139","id":"PMC_36272139","title":"A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastoma.","date":"2023","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36272139","citation_count":51,"is_preprint":false},{"pmid":"29225516","id":"PMC_29225516","title":"Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma.","date":"2017","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/29225516","citation_count":50,"is_preprint":false},{"pmid":"18473722","id":"PMC_18473722","title":"Role of mismatch repair and MGMT in response to anticancer therapies.","date":"2008","source":"Anti-cancer agents in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18473722","citation_count":49,"is_preprint":false},{"pmid":"25394859","id":"PMC_25394859","title":"Treatment considerations for MGMT-unmethylated glioblastoma.","date":"2015","source":"Current neurology and neuroscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/25394859","citation_count":49,"is_preprint":false},{"pmid":"30542120","id":"PMC_30542120","title":"Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30542120","citation_count":47,"is_preprint":false},{"pmid":"37451151","id":"PMC_37451151","title":"Quercetin induces MGMT+ glioblastoma cells apoptosis via dual inhibition of Wnt3a/β-Catenin and Akt/NF-κB signaling pathways.","date":"2023","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37451151","citation_count":44,"is_preprint":false},{"pmid":"38242327","id":"PMC_38242327","title":"MGMT in TMZ-based glioma therapy: Multifaceted insights and clinical trial perspectives.","date":"2024","source":"Biochimica et biophysica acta. Molecular cell research","url":"https://pubmed.ncbi.nlm.nih.gov/38242327","citation_count":40,"is_preprint":false},{"pmid":"21708177","id":"PMC_21708177","title":"O(6)-methylguanine-DNA methyltransferase (MGMT): impact on cancer risk in response to tobacco smoke.","date":"2011","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/21708177","citation_count":39,"is_preprint":false},{"pmid":"17325429","id":"PMC_17325429","title":"MGMT methylation status: the advent of stratified therapy in glioblastoma?","date":"2007","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/17325429","citation_count":39,"is_preprint":false},{"pmid":"17569599","id":"PMC_17569599","title":"Genetic association and functional studies of major polymorphic variants of MGMT.","date":"2007","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/17569599","citation_count":38,"is_preprint":false},{"pmid":"24568970","id":"PMC_24568970","title":"The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide.","date":"2014","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/24568970","citation_count":38,"is_preprint":false},{"pmid":"19224454","id":"PMC_19224454","title":"MGMT analysis at DNA, RNA and protein levels in glioblastoma tissue.","date":"2009","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/19224454","citation_count":36,"is_preprint":false},{"pmid":"25777962","id":"PMC_25777962","title":"MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide.","date":"2015","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/25777962","citation_count":36,"is_preprint":false},{"pmid":"32007918","id":"PMC_32007918","title":"Inhibition of MGMT-mediated autophagy suppression decreases cisplatin chemosensitivity in gastric cancer.","date":"2020","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/32007918","citation_count":36,"is_preprint":false},{"pmid":"30549269","id":"PMC_30549269","title":"Profound, durable and MGMT-independent sensitivity of glioblastoma cells to cyclin-dependent kinase inhibition.","date":"2019","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30549269","citation_count":33,"is_preprint":false},{"pmid":"32039031","id":"PMC_32039031","title":"MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas.","date":"2020","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32039031","citation_count":33,"is_preprint":false},{"pmid":"23716983","id":"PMC_23716983","title":"MGMT and MLH1 methylation in Helicobacter pylori-infected children and adults.","date":"2013","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/23716983","citation_count":33,"is_preprint":false},{"pmid":"31798765","id":"PMC_31798765","title":"HDAC8 affects MGMT levels in glioblastoma cell lines via interaction with the proteasome receptor ADRM1.","date":"2019","source":"Genes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31798765","citation_count":33,"is_preprint":false},{"pmid":"17482889","id":"PMC_17482889","title":"MGMT: a personal perspective.","date":"2007","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/17482889","citation_count":32,"is_preprint":false},{"pmid":"29848907","id":"PMC_29848907","title":"MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas.","date":"2018","source":"Neurologia medico-chirurgica","url":"https://pubmed.ncbi.nlm.nih.gov/29848907","citation_count":32,"is_preprint":false},{"pmid":"32354046","id":"PMC_32354046","title":"The Role of miRNA for the Treatment of MGMT Unmethylated Glioblastoma Multiforme.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32354046","citation_count":29,"is_preprint":false},{"pmid":"21822153","id":"PMC_21822153","title":"O-6-methylguanine-DNA methyltransferase (MGMT) immunohistochemical expression in pituitary corticotroph adenomas.","date":"2012","source":"Neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/21822153","citation_count":28,"is_preprint":false},{"pmid":"20585787","id":"PMC_20585787","title":"MGMT gene promoter methylation in pediatric glioblastomas.","date":"2010","source":"Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/20585787","citation_count":27,"is_preprint":false},{"pmid":"25516857","id":"PMC_25516857","title":"Role of MGMT as biomarker in colorectal cancer.","date":"2014","source":"World journal of clinical cases","url":"https://pubmed.ncbi.nlm.nih.gov/25516857","citation_count":27,"is_preprint":false},{"pmid":"31740551","id":"PMC_31740551","title":"Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/31740551","citation_count":27,"is_preprint":false},{"pmid":"38277015","id":"PMC_38277015","title":"Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma.","date":"2024","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/38277015","citation_count":26,"is_preprint":false},{"pmid":"37634280","id":"PMC_37634280","title":"Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastoma.","date":"2023","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/37634280","citation_count":24,"is_preprint":false},{"pmid":"26202203","id":"PMC_26202203","title":"Posttranslational Regulation of O(6)-Methylguanine-DNA Methyltransferase (MGMT) and New Opportunities for Treatment of Brain Cancers.","date":"2016","source":"Mini reviews in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26202203","citation_count":24,"is_preprint":false},{"pmid":"19892775","id":"PMC_19892775","title":"Effects of O6-methylguanine-DNA methyltransferase (MGMT) polymorphisms on cancer: a meta-analysis.","date":"2009","source":"Mutagenesis","url":"https://pubmed.ncbi.nlm.nih.gov/19892775","citation_count":24,"is_preprint":false},{"pmid":"26518768","id":"PMC_26518768","title":"MGMT testing allows for personalised therapy in the temozolomide era.","date":"2015","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26518768","citation_count":24,"is_preprint":false},{"pmid":"28900805","id":"PMC_28900805","title":"MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas.","date":"2017","source":"Pituitary","url":"https://pubmed.ncbi.nlm.nih.gov/28900805","citation_count":24,"is_preprint":false},{"pmid":"28848211","id":"PMC_28848211","title":"Association Between MGMT Promoter Methylation and Breast Cancer: a Meta-Analysis.","date":"2017","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28848211","citation_count":23,"is_preprint":false},{"pmid":"31865606","id":"PMC_31865606","title":"IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.","date":"2019","source":"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico","url":"https://pubmed.ncbi.nlm.nih.gov/31865606","citation_count":23,"is_preprint":false},{"pmid":"37524206","id":"PMC_37524206","title":"Modulating MGMT expression through interfering with cell signaling pathways.","date":"2023","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37524206","citation_count":22,"is_preprint":false},{"pmid":"23414134","id":"PMC_23414134","title":"Correlation of MLH1 and MGMT expression and promoter methylation with genomic instability in patients with thyroid carcinoma.","date":"2013","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23414134","citation_count":22,"is_preprint":false},{"pmid":"22798502","id":"PMC_22798502","title":"MGMT hypermethylation and MDR system in glioblastoma cancer stem cells.","date":"2012","source":"Cancer genomics & proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/22798502","citation_count":21,"is_preprint":false},{"pmid":"28001451","id":"PMC_28001451","title":"MGMT hypomethylation is associated with DNA damage in workers exposed to low-dose benzene.","date":"2017","source":"Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/28001451","citation_count":21,"is_preprint":false},{"pmid":"32721465","id":"PMC_32721465","title":"MGMT expression affects the gemcitabine resistance of pancreatic cancer cells.","date":"2020","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32721465","citation_count":20,"is_preprint":false},{"pmid":"24397721","id":"PMC_24397721","title":"Immunohistochemical evaluation of O6 -methylguanine DNA methyltransferase (MGMT) expression in 117 cases of glioblastoma.","date":"2014","source":"Neuropathology : official journal of the Japanese Society of Neuropathology","url":"https://pubmed.ncbi.nlm.nih.gov/24397721","citation_count":20,"is_preprint":false},{"pmid":"22609488","id":"PMC_22609488","title":"Progress in high-throughput assays of MGMT and APE1 activities in cell extracts.","date":"2012","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/22609488","citation_count":20,"is_preprint":false},{"pmid":"30444735","id":"PMC_30444735","title":"MGMT Testing in Glioblastomas: Pitfalls and Opportunities.","date":"2019","source":"American journal of clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30444735","citation_count":19,"is_preprint":false},{"pmid":"17569600","id":"PMC_17569600","title":"Lung cancer risk and variation in MGMT activity and sequence.","date":"2007","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/17569600","citation_count":19,"is_preprint":false},{"pmid":"36513631","id":"PMC_36513631","title":"BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36513631","citation_count":19,"is_preprint":false},{"pmid":"33209885","id":"PMC_33209885","title":"Blocking MAPK/ERK pathway sensitizes hepatocellular carcinoma cells to temozolomide via downregulating MGMT expression.","date":"2020","source":"Annals of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33209885","citation_count":19,"is_preprint":false},{"pmid":"27492578","id":"PMC_27492578","title":"O6-Methylguanine-DNA methyltransferase (MGMT): A drugable target in lung cancer?","date":"2016","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/27492578","citation_count":18,"is_preprint":false},{"pmid":"36242092","id":"PMC_36242092","title":"PARP1-MGMT complex underpins pathway crosstalk in O6-methylguanine repair.","date":"2022","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36242092","citation_count":18,"is_preprint":false},{"pmid":"35219686","id":"PMC_35219686","title":"LncRNA UCA1/miR-182-5p/MGMT axis modulates glioma cell sensitivity to temozolomide through MGMT-related DNA damage pathways.","date":"2022","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/35219686","citation_count":18,"is_preprint":false},{"pmid":"32698158","id":"PMC_32698158","title":"Critical appraisal of MGMT in digestive NET treated with alkylating agents.","date":"2020","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32698158","citation_count":18,"is_preprint":false},{"pmid":"33041828","id":"PMC_33041828","title":"Tim-3 Expression and MGMT Methylation Status Association With Survival in Glioblastoma.","date":"2020","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33041828","citation_count":17,"is_preprint":false},{"pmid":"30673883","id":"PMC_30673883","title":"Predictive markers for MGMT promoter methylation in glioblastomas.","date":"2019","source":"Neurosurgical review","url":"https://pubmed.ncbi.nlm.nih.gov/30673883","citation_count":17,"is_preprint":false},{"pmid":"24938706","id":"PMC_24938706","title":"Aberrant DNA methylation of MGMT and hMLH1 genes in prediction of gastric cancer.","date":"2014","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/24938706","citation_count":16,"is_preprint":false},{"pmid":"22797801","id":"PMC_22797801","title":"MGMT expression and pituitary tumours: relationship to tumour biology.","date":"2013","source":"Pituitary","url":"https://pubmed.ncbi.nlm.nih.gov/22797801","citation_count":16,"is_preprint":false},{"pmid":"2233795","id":"PMC_2233795","title":"The control of O6-methylguanine-DNA methyltransferase (MGMT) activity in mammalian cells: a pre-molecular view.","date":"1990","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/2233795","citation_count":16,"is_preprint":false},{"pmid":"29801405","id":"PMC_29801405","title":"O6-Methyguanine-DNA Methyl Transferase (MGMT) Promoter Methylation in Serum DNA of Iranian Patients with Colorectal Cancer.","date":"2018","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/29801405","citation_count":16,"is_preprint":false},{"pmid":"34016221","id":"PMC_34016221","title":"Evaluation of MGMT Gene Methylation in Neuroendocrine Neoplasms.","date":"2021","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/34016221","citation_count":15,"is_preprint":false},{"pmid":"39356744","id":"PMC_39356744","title":"Dynamic structural remodeling of LINC01956 enhances temozolomide resistance in MGMT-methylated glioblastoma.","date":"2024","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39356744","citation_count":14,"is_preprint":false},{"pmid":"24151575","id":"PMC_24151575","title":"Toward a Molecular Classification of Colorectal Cancer: The Role of MGMT.","date":"2013","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24151575","citation_count":14,"is_preprint":false},{"pmid":"36261081","id":"PMC_36261081","title":"Organochlorine pesticides may induce leukemia by methylation of CDKN2B and MGMT promoters and histone modifications.","date":"2022","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/36261081","citation_count":13,"is_preprint":false},{"pmid":"34976195","id":"PMC_34976195","title":"Clinical strategies to manage adult glioblastoma patients without MGMT hypermethylation.","date":"2022","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34976195","citation_count":13,"is_preprint":false},{"pmid":"28436299","id":"PMC_28436299","title":"MGMT gene variants, temozolomide myelotoxicity and glioma risk. A concise literature survey including an illustrative case.","date":"2017","source":"Journal of chemotherapy (Florence, Italy)","url":"https://pubmed.ncbi.nlm.nih.gov/28436299","citation_count":13,"is_preprint":false},{"pmid":"30677446","id":"PMC_30677446","title":"Germline variation in O6-methylguanine-DNA methyltransferase (MGMT) as cause of hereditary colorectal cancer.","date":"2019","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/30677446","citation_count":13,"is_preprint":false},{"pmid":"34202589","id":"PMC_34202589","title":"Lomeguatrib Increases the Radiosensitivity of MGMT Unmethylated Human Glioblastoma Multiforme Cell Lines.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34202589","citation_count":13,"is_preprint":false},{"pmid":"30038102","id":"PMC_30038102","title":"MGMT gene promoter methylation and its correlation with clinicopathological parameters in glioblastomas.","date":"2018","source":"Neurology India","url":"https://pubmed.ncbi.nlm.nih.gov/30038102","citation_count":12,"is_preprint":false},{"pmid":"37286145","id":"PMC_37286145","title":"Magnolol and Temozolomide exhibit a synergistic anti-glioma activity through MGMT inhibition.","date":"2023","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/37286145","citation_count":12,"is_preprint":false},{"pmid":"38762829","id":"PMC_38762829","title":"Enhancing Temozolomide (TMZ) chemosensitivity using CRISPR-dCas9-mediated downregulation of O6-methylguanine DNA methyltransferase (MGMT).","date":"2024","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/38762829","citation_count":12,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52606,"output_tokens":6538,"usd":0.127944,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15510,"output_tokens":4388,"usd":0.093625,"stage2_stop_reason":"end_turn"},"total_usd":0.221569,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2007,\n      \"finding\": \"MGMT is a suicide enzyme (alkyltransferase) that repairs O6-alkylguanine DNA lesions by irreversibly transferring the alkyl group from the O6 position of guanine to a cysteine residue in its own active site (Cys145), thereby becoming inactivated in the process. It also repairs larger adducts at the O6-position such as O6-chloroethylguanine.\",\n      \"method\": \"In vitro biochemical assays, active-site characterization, review of mechanistic studies\",\n      \"journal\": \"DNA repair\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — catalytic mechanism (suicide alkyltransferase, active-site Cys) established by multiple independent biochemical studies and replicated across labs over decades\",\n      \"pmids\": [\"17485253\", \"11981013\", \"17482889\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"O6-methylguanine (O6-MeG) induced by MGMT-repaired lesions causes cell death and clastogenicity via a mechanism that requires MutS-alpha-dependent mismatch repair (MMR), whereas O6-chloroethylguanine-induced killing occurs independently of MMR. Extensive DNA replication is required for O6-MeG to provoke cytotoxicity, and the secondary DNA double-strand breaks trigger apoptosis via ATM/ATR, Chk1, Chk2, p53, and p73.\",\n      \"method\": \"Genetic epistasis using MGMT-modulated and MMR-deficient cell systems; apoptosis pathway analysis\",\n      \"journal\": \"DNA repair\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — epistasis experiments across multiple cell lines, replicated across labs, mechanistic pathway placement established\",\n      \"pmids\": [\"17485253\", \"11554312\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"In MGMT-deficient cells, O6-methylguanine is the major genotoxic, recombinogenic, and apoptotic lesion; its cytotoxicity requires mismatch repair. In cells with high MGMT expression or low O6-methylguanine formation, N-alkylation lesions repaired by base excision repair (BER) become the dominant genotoxic lesions.\",\n      \"method\": \"Genetic modulation (transfection, mutational inactivation) of MGMT and BER components; cell survival assays\",\n      \"journal\": \"Progress in nucleic acid research and molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function and gain-of-function experiments across multiple DNA repair pathways with defined phenotypic readouts, replicated\",\n      \"pmids\": [\"11554312\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Epigenetic silencing of MGMT by promoter CpG island methylation suppresses MGMT expression in glioblastoma, and this silencing predicts benefit from temozolomide chemotherapy. Promoter methylation was confirmed as the key mechanism of MGMT gene silencing.\",\n      \"method\": \"Methylation-specific PCR of tumor tissue from a randomized clinical trial; correlation with survival outcomes\",\n      \"journal\": \"The New England journal of medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — prospective randomized trial with molecular assay, independently replicated across multiple cohorts\",\n      \"pmids\": [\"15758010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Dimethylation of histone H3 lysine 9 and binding of methyl-CpG binding proteins are common and essential epigenetic marks in MGMT-silenced cancer cells, and MGMT silencing can occur without DNA hypermethylation in some cancer cells.\",\n      \"method\": \"Chromatin immunoprecipitation and analysis of histone modifications in MGMT-silenced cell lines\",\n      \"journal\": \"Biochemistry and cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — chromatin analysis in silenced cells, single lab, limited orthogonal validation reported in abstract\",\n      \"pmids\": [\"16094446\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"In MGMT-methylated glioblastoma, MGMT promoter methylation correlates with a non-permissive chromatin status, very low MGMT transcript levels, and undetectable MGMT enzymatic activity, demonstrating functional linkage between epigenetic silencing and loss of repair capacity.\",\n      \"method\": \"Chromatin status analysis, real-time PCR for MGMT transcript, MGMT activity assay in paired glioblastoma and glioblastoma-derived sphere samples\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — multiple orthogonal methods (chromatin, RNA, enzymatic activity) in same study, single lab\",\n      \"pmids\": [\"21097691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"NDRG1 (an mTOR target induced by hypoxia, irradiation, corticosteroids, and chronic alkylating agent exposure) binds and stabilizes MGMT protein, thereby conferring MGMT-dependent resistance to alkylating chemotherapy in glioblastoma.\",\n      \"method\": \"Co-immunoprecipitation, Western blot, NDRG1 knockdown/overexpression, in vivo tumor models\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP demonstrating NDRG1-MGMT complex, functional rescue experiments, in vivo validation\",\n      \"pmids\": [\"24367102\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In MGMT-deficient tumor cells, temozolomide activates the ATR-Chk1 signaling axis (inducing DNA double-strand breaks and G2-M arrest leading to ATR-dependent Chk1 phosphorylation) in an MGMT-status-dependent manner, and this sensitizes MGMT-deficient cells to ATR inhibitors both in vitro and in vivo.\",\n      \"method\": \"Cell viability assays, DNA damage markers (γ-H2AX), cell cycle analysis, ATR inhibitor combination in vitro and in vivo across multiple tumor cell types\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods, multiple cell types, in vivo confirmation, mechanistic pathway (MGMT→ATR-Chk1) established\",\n      \"pmids\": [\"31273061\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PARP1 and MGMT interact directly in a DNA-independent manner; upon DNA damage, PARP1 PARylates MGMT, and this PARylation enhances O6-methylguanine repair, revealing functional crosstalk between BER (PARP1) and MGMT-mediated direct reversal repair pathways.\",\n      \"method\": \"Co-immunoprecipitation, in vitro PARylation assay, DNA damage-inducible complex formation, chromatin binding assays\",\n      \"journal\": \"Journal of hematology & oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — direct protein interaction demonstrated by Co-IP and in vitro PARylation assay with functional readout (enhanced O6meG repair), multiple orthogonal methods\",\n      \"pmids\": [\"36242092\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Post-translational modifications of MGMT including ubiquitination, sumoylation, and glutathionylation affect MGMT protein stability and DNA repair activity. The active site Cys145 can be targeted by thiol-reacting compounds (e.g., disulfiram, dithiocarbamates) to inactivate and deplete MGMT.\",\n      \"method\": \"Biochemical assays of PTM effects on MGMT stability and activity; active-site mutagenesis and chemical inhibition studies\",\n      \"journal\": \"Mini reviews in medicinal chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Weak — PTM effects reviewed from experimental data but described in a review/mini-review context; individual experiments from multiple labs\",\n      \"pmids\": [\"26202203\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MGMT activates DUB3 transcription, and the resulting MGMT-DUB3-MCL1 axis promotes chemoresistance in ovarian cancer: DUB3 interacts with and deubiquitinates MCL1 in the cytoplasm, protecting MCL1 from proteasomal degradation.\",\n      \"method\": \"Co-immunoprecipitation (DUB3-MCL1 interaction), transcriptional reporter assays (MGMT activating DUB3), in vitro and in vivo functional studies with MGMT inhibitor PaTrin-2\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP for DUB3-MCL1 interaction, transcriptional activation of DUB3 by MGMT, in vivo validation, single lab\",\n      \"pmids\": [\"30718431\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"An enhancer located between the MKI67 and MGMT gene promoters is activated in temozolomide-resistant glioblastoma; forced activation of this enhancer increases MGMT expression, and CRISPR/Cas9-mediated deletion of the enhancer reduces MGMT expression and restores temozolomide sensitivity.\",\n      \"method\": \"CRISPR/Cas9 enhancer deletion and activation, gene expression analysis, TMZ sensitivity assays in patient-derived xenograft lines and recurrent tumor samples\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — CRISPR gain- and loss-of-function at defined genomic locus with functional readout (MGMT expression and TMZ sensitivity), PDX models\",\n      \"pmids\": [\"30054476\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"NF-κB signaling regulates MGMT expression: NF-κB inhibition by MG-132 decreases MGMT expression in glioma stem-like cells and enhances temozolomide sensitivity in MGMT-positive GSCs.\",\n      \"method\": \"NF-κB inhibitor (MG-132) treatment, Western blot for MGMT, cell viability/IC50 assays in glioma stem-like cells\",\n      \"journal\": \"Chinese journal of cancer\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single inhibitor experiment, indirect pathway modulation, single lab, no direct promoter binding demonstrated\",\n      \"pmids\": [\"23958055\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Hedgehog/Gli1 signaling pathway regulates MGMT expression independently of MGMT promoter methylation. Gli1 binds a site at -411 to -403 bp upstream of the MGMT transcriptional start site, and activation or inhibition of Gli1 increases or decreases MGMT expression and TMZ resistance respectively.\",\n      \"method\": \"Chromatin immunoprecipitation identifying Gli1 binding site in MGMT promoter, Gli1 overexpression/inhibition (cyclopamine), methylation-specific PCR, in vivo xenograft model\",\n      \"journal\": \"Cancer cell international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP identifies direct Gli1 binding at MGMT promoter, functional gain/loss-of-function with in vivo validation, single lab\",\n      \"pmids\": [\"29225516\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Fstl1 regulates MGMT expression via the DIP2A/HDAC2-DMAP1 axis: DIP2A cooperates with the HDAC2-DMAP1 complex to enhance H3K9Ac deacetylation at the MGMT promoter and suppress MGMT transcription. Fstl1 competitively binds DIP2A to block its nuclear translocation, preventing DIP2A from binding the HDAC2-DMAP1 complex and resulting in increased H3K9Ac and MGMT expression.\",\n      \"method\": \"Co-immunoprecipitation (Fstl1-DIP2A, DIP2A-HDAC2-DMAP1), nuclear fractionation, ChIP (H3K9Ac at MGMT promoter), knockdown/overexpression, in vivo and in vitro TMZ resistance assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, ChIP showing histone modification at MGMT promoter, DIP2A rescue experiment, in vivo validation, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"30542120\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HDAC8 regulates MGMT protein levels via interaction with the proteasome receptor ADRM1. HDAC8 inhibition decreases MGMT protein levels in glioblastoma cell lines independently of MGMT promoter methylation status; this interaction between HDAC8 and ADRM1 is disrupted by temozolomide exclusively in TMZ-sensitive cells.\",\n      \"method\": \"HDAC8-specific inhibitor and shRNA knockdown, ADRM1 interaction studies (Co-IP), Western blot for MGMT, cell viability assays\",\n      \"journal\": \"Genes & cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP for HDAC8-ADRM1 interaction, shRNA and pharmacological inhibition with functional MGMT readout, single lab\",\n      \"pmids\": [\"31798765\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BET protein inhibition (BETi) reduces MGMT expression in glioblastoma cells by reducing BRD4 and RNA polymerase II binding at the MGMT promoter. BETi also inhibits temozolomide-induced MGMT upregulation; ectopic MGMT expression under an unrelated promoter is unaffected by BETi, confirming the mechanism is transcriptional and promoter-specific.\",\n      \"method\": \"ChIP for BRD4 and Pol II at MGMT promoter, ectopic MGMT overexpression controls, γ-H2AX assay, BETi treatment in glioblastoma-derived spheres\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrating BRD4/Pol II at MGMT promoter, mechanistic rescue experiment with ectopic MGMT, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"36513631\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MGMT genomic rearrangements (structural variants) in recurrent gliomas lead to MGMT overexpression independently of promoter methylation changes; CRISPR/Cas9-generated MGMT rearrangements in glioma cells confer temozolomide resistance both in vitro and in vivo.\",\n      \"method\": \"CRISPR/Cas9-mediated genomic rearrangements, gene expression analysis, in vitro and in vivo TMZ resistance assays, exosome detection of fusion transcripts\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR-generated structural variants with functional TMZ resistance readout in vitro and in vivo, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"32753598\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Gene body cytosine modifications in the MGMT locus positively regulate MGMT expression independently of promoter methylation; inducing gene body hypomethylation with decitabine decreases MGMT expression in glioblastoma and lymphoblastoid cell lines and sensitizes resistant cells to temozolomide.\",\n      \"method\": \"Methylation analysis of 91 glioblastoma samples, decitabine treatment with MGMT expression measurement, TMZ sensitivity assays\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional intervention (decitabine) with MGMT expression and drug sensitivity readout, supported by human tumor data; single lab\",\n      \"pmids\": [\"24568970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MGMT suppresses ATG4B expression in gastric cancer cells, thereby inhibiting autophagy; cisplatin inhibits MGMT, which leads to ATG4B upregulation, increased autophagy, and decreased chemosensitivity. MGMT inhibition-mediated ATG4B derepression drives autophagy-dependent DDP resistance.\",\n      \"method\": \"MGMT knockdown/inhibition, ATG4B expression analysis, autophagy assays, in vivo xenograft model with chloroquine combination\",\n      \"journal\": \"Biomedicine & pharmacotherapy\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — indirect regulation of ATG4B by MGMT, mechanistic link inferred from inhibitor studies; single lab, limited mechanistic detail in abstract\",\n      \"pmids\": [\"32007918\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In MGMT-methylated glioblastoma cells, temozolomide activates CHK1, which phosphorylates the RNA helicase DDX46, inducing a dense-to-loose conformational change that increases DDX46 helicase activity. DDX46-mediated structural remodeling of lncRNA LINC01956 exposes binding motifs that interact with the 3'UTR of MGMT mRNA, promoting nuclear export and increased MGMT protein abundance, thus driving TMZ resistance.\",\n      \"method\": \"RNA immunoprecipitation (RIP), CLIP, structural analysis, mRNA export assays, PDX and tumor organoid models, CHK1 inhibitor rescue experiments\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (RIP, structural remodeling, mRNA export), mechanistic rescue with CHK1 inhibitor, PDX and organoid models, single lab\",\n      \"pmids\": [\"39356744\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"MGMT expression and promoter methylation exhibit intrinsic circadian rhythms in glioblastoma cells; MGMT activity is lowest at the daily peak of Bmal1 transcription, and TMZ sensitivity correspondingly peaks at this time. Inhibition of MGMT activity with O6-benzylguanine abolishes the daily rhythm in TMZ sensitivity.\",\n      \"method\": \"Real-time bioluminescence reporters for circadian clock genes and MGMT, MGMT transcript and methylation time-course analysis, TMZ viability assays at different circadian times, in vivo xenograft morning vs. evening TMZ delivery\",\n      \"journal\": \"Journal of neuro-oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (reporter, transcript, methylation, functional TMZ rescue with O6-BG), in vivo confirmation, single lab\",\n      \"pmids\": [\"38277015\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"MGMT-positive cancer cells show strong dependence on PARP for survival under temozolomide treatment; in vitro and in vivo, MGMT-positive (but not MGMT-deficient) cells are highly sensitive to the combination of temozolomide and PARP inhibitors, with MGMT-positive melanoma cells undergoing enhanced senescence.\",\n      \"method\": \"In vitro cell viability assays, in vivo tumor models, PARP inhibitor combination studies stratified by MGMT expression\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo combination studies with MGMT-stratified cells, single lab\",\n      \"pmids\": [\"25777962\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"MGMT polymorphic variants Leu84Phe, Ile143Val, and Lys178Arg have subtle effects on alkyltransferase activity; studies in cells show these variants do not dramatically alter repair function. The proposed role of alkylated MGMT in modifying Estrogen Receptor alpha activity was not confirmed as a major function in experimental studies.\",\n      \"method\": \"Alkyltransferase activity assays of polymorphic variants, ER-alpha transcriptional reporter assays\",\n      \"journal\": \"DNA repair\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro enzymatic activity measurement of variants plus negative result for ER-alpha modulation; single lab\",\n      \"pmids\": [\"17569599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"A high-throughput MGMT activity assay was developed based on the mechanism whereby MGMT irreversibly transfers the alkyl group from O6-position guanine to its active site cysteine; biotin-tagged O6-benzylguanine (a substrate analog) is transferred to MGMT, forming a MGMT-BG-biotin complex that can be captured on anti-MGMT-coated plates and quantified.\",\n      \"method\": \"Biochemical assay development using MGMT's suicide mechanism; validation in cell extracts with streptavidin-alkaline phosphatase detection\",\n      \"journal\": \"Mutation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro biochemical assay exploiting catalytic mechanism, validated across samples; assay development paper\",\n      \"pmids\": [\"22609488\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IKBKE enhances temozolomide resistance in glioblastoma cells by activating the AKT/NF-κB signaling pathway, which upregulates MGMT expression; IKBKE knockdown reduces MGMT levels and sensitizes cells to TMZ in vitro and in vivo.\",\n      \"method\": \"IKBKE knockdown/overexpression, Western blot for MGMT and AKT/NF-κB pathway components, cell proliferation and apoptosis assays, in vivo intracranial xenograft model\",\n      \"journal\": \"Clinical & translational oncology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pathway inhibition with MGMT readout, indirect regulation via AKT/NF-κB, single lab, no direct promoter binding shown\",\n      \"pmids\": [\"31865606\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MGMT is a suicide DNA repair alkyltransferase that directly removes alkyl adducts (principally O6-methylguanine) from DNA by irreversible transfer to its active-site Cys145, causing self-inactivation; unrepaired O6-MeG triggers MMR-dependent DNA double-strand breaks activating the ATM/ATR→Chk1/Chk2→p53/p73 apoptotic cascade, while MGMT expression is regulated at multiple levels including promoter CpG methylation (linked to non-permissive chromatin marked by H3K9 dimethylation and reduced BRD4/Pol II occupancy), transcriptional control by Gli1 and NF-κB, an intergenic enhancer, post-translational stabilization by NDRG1 and HDAC8/ADRM1, PARylation by PARP1 (which enhances O6-MeG repair), and post-transcriptional nuclear export via CHK1-phospho-DDX46-remodeled LINC01956; additionally, MGMT activates the DUB3–MCL1 anti-apoptotic axis in a non-canonical function.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MGMT is a suicide DNA repair alkyltransferase that directly reverses alkylation damage by irreversibly transferring the alkyl group from the O6 position of guanine to its own active-site cysteine (Cys145), inactivating itself in the process and also handling larger O6 adducts such as O6-chloroethylguanine [#0]. Its central biological importance lies in determining cytotoxic outcome of alkylating agents: unrepaired O6-methylguanine is the dominant genotoxic, recombinogenic and apoptotic lesion, and its killing requires MutS-alpha-dependent mismatch repair and extensive replication, generating secondary double-strand breaks that activate an ATM/ATR\\u2192Chk1/Chk2\\u2192p53/p73 apoptotic cascade [#1, #2]. This mechanism makes MGMT status the principal determinant of temozolomide response, and epigenetic silencing of MGMT by promoter CpG-island methylation\\u2014linked to a non-permissive chromatin state and loss of transcript and enzymatic activity\\u2014predicts clinical benefit from temozolomide in glioblastoma [#3, #5]. MGMT abundance is controlled at multiple additional layers: transcriptionally through a Gli1 binding site, an intergenic MKI67\\u2013MGMT enhancer, BRD4/Pol II occupancy, and HDAC2\\u2013DMAP1\\u2013mediated histone deacetylation antagonized by Fstl1\\u2013DIP2A [#13, #11, #16, #14]; through gene-body cytosine modification and genomic rearrangements that drive overexpression independent of promoter methylation [#18, #17]; and post-translationally via NDRG1 binding and stabilization and HDAC8\\u2013ADRM1 control of protein turnover [#6, #15]. MGMT also engages in functional crosstalk with base-excision repair through direct DNA-independent interaction with PARP1, which PARylates MGMT to enhance O6-methylguanine repair [#8]. Beyond repair, MGMT exerts a non-canonical pro-survival role by transcriptionally activating DUB3 to stabilize the anti-apoptotic protein MCL1, promoting chemoresistance [#10], and a CHK1\\u2013DDX46\\u2013LINC01956 axis remodels MGMT mRNA to promote its nuclear export and protein accumulation under temozolomide stress [#20].\",\n  \"teleology\": [\n    {\n      \"year\": 2007,\n      \"claim\": \"Established the core catalytic mechanism: how MGMT removes mutagenic O6-alkyl lesions, defining it as a single-turnover suicide enzyme.\",\n      \"evidence\": \"In vitro biochemical and active-site characterization showing irreversible alkyl transfer to Cys145\",\n      \"pmids\": [\"17485253\", \"11981013\", \"17482889\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not address how spent MGMT is degraded or recycled in vivo\", \"No structural detail on substrate selectivity for larger adducts\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Resolved why MGMT loss is cytotoxic by placing unrepaired O6-methylguanine downstream of mismatch repair and within an ATM/ATR\\u2192Chk\\u2192p53/p73 apoptotic cascade.\",\n      \"evidence\": \"Genetic epistasis in MGMT-modulated and MMR-deficient cells with apoptosis pathway analysis\",\n      \"pmids\": [\"17485253\", \"11554312\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Exact molecular trigger converting O6-MeG mispairs to double-strand breaks not fully defined\", \"Relative contribution of p53 vs p73 unresolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Defined the lesion hierarchy dictated by MGMT level, showing O6-MeG dominates genotoxicity in MGMT-deficient cells while BER-repaired N-alkylations dominate when MGMT is high.\",\n      \"evidence\": \"Gain/loss-of-function modulation of MGMT and BER components with survival readouts\",\n      \"pmids\": [\"11554312\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative thresholds of MGMT activity setting the switch not established\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Connected MGMT promoter CpG methylation to gene silencing and to clinical temozolomide benefit, making MGMT status a predictive biomarker.\",\n      \"evidence\": \"Methylation-specific PCR on randomized-trial glioblastoma tissue correlated with survival\",\n      \"pmids\": [\"15758010\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not explain methylation-independent silencing or reactivation\", \"Assay does not measure enzymatic activity directly\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Confirmed that promoter methylation translates into functional loss by linking non-permissive chromatin to undetectable transcript and enzymatic activity.\",\n      \"evidence\": \"Chromatin, RT-PCR and activity assays in paired glioblastoma and sphere samples; H3K9 dimethylation and methyl-CpG binding marks defined in silenced cells\",\n      \"pmids\": [\"21097691\", \"16094446\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism establishing the silenced chromatin state not defined\", \"Methylation-independent silencing in some cells unexplained\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified post-translational stabilization as a resistance mechanism, showing NDRG1 binds and stabilizes MGMT protein independent of transcription.\",\n      \"evidence\": \"Reciprocal Co-IP, knockdown/overexpression and in vivo tumor models\",\n      \"pmids\": [\"24367102\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of NDRG1-MGMT binding unknown\", \"Whether NDRG1 blocks specific degradation pathway not defined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Revealed methylation-independent transcriptional control by mapping a direct Gli1 binding site upstream of the MGMT start site.\",\n      \"evidence\": \"ChIP, Gli1 gain/loss-of-function and xenograft validation\",\n      \"pmids\": [\"29225516\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; cooperating transcription factors at the promoter not mapped\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated distal and chromatin-level transcriptional regulation through an intergenic MKI67-MGMT enhancer and Fstl1-DIP2A-controlled histone acetylation.\",\n      \"evidence\": \"CRISPR enhancer deletion/activation and reciprocal Co-IP/ChIP for the Fstl1-DIP2A-HDAC2-DMAP1 axis in PDX and resistant models\",\n      \"pmids\": [\"30054476\", \"30542120\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interplay between enhancer activity and promoter methylation not resolved\", \"Upstream signals controlling Fstl1/DIP2A nuclear shuttling unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed gene-body methylation positively regulates MGMT, distinguishing it from repressive promoter methylation and providing a decitabine-sensitive node.\",\n      \"evidence\": \"Methylation profiling of 91 tumors plus decitabine intervention with expression and TMZ readouts\",\n      \"pmids\": [\"24568970\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reader/effector linking gene-body methylation to transcription not identified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Uncovered a CHK1-engaging therapeutic vulnerability and a non-canonical pro-survival output, with MGMT-deficient cells sensitized to ATR inhibition and MGMT activating a DUB3-MCL1 anti-apoptotic axis.\",\n      \"evidence\": \"ATR/Chk1 damage and inhibitor combination studies; Co-IP and transcriptional reporter assays for the MGMT-DUB3-MCL1 axis with in vivo validation\",\n      \"pmids\": [\"31273061\", \"30718431\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How MGMT transcriptionally activates DUB3 mechanistically undefined\", \"DUB3-MCL1 axis tested mainly in ovarian cancer context\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Extended protein-level control by linking HDAC8-ADRM1 to MGMT turnover, providing a methylation-independent way to deplete MGMT pharmacologically.\",\n      \"evidence\": \"HDAC8 inhibition/shRNA and HDAC8-ADRM1 Co-IP with MGMT and viability readouts\",\n      \"pmids\": [\"31798765\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; whether HDAC8 acts via deacetylation or scaffolding of ADRM1 unresolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established direct repair-pathway crosstalk by demonstrating PARP1 binds and PARylates MGMT to enhance O6-MeG repair, and that MGMT-positive cells depend on PARP under temozolomide.\",\n      \"evidence\": \"Co-IP, in vitro PARylation and chromatin-binding assays; MGMT-stratified PARP inhibitor combination studies in vitro and in vivo\",\n      \"pmids\": [\"36242092\", \"25777962\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"PARylation site(s) on MGMT and effect on its suicide mechanism not mapped\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined post-transcriptional and chronobiological control of MGMT, with a CHK1-DDX46-LINC01956 axis driving MGMT mRNA export and intrinsic circadian rhythms in MGMT activity dictating temozolomide timing sensitivity.\",\n      \"evidence\": \"RIP/CLIP, mRNA export assays and CHK1 inhibitor rescue in PDX/organoids; circadian bioluminescence reporters with timed TMZ dosing and O6-benzylguanine rescue\",\n      \"pmids\": [\"39356744\", \"38277015\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality of the LINC01956 mechanism beyond methylated glioblastoma untested\", \"Clock components directly driving MGMT promoter rhythmicity not identified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the diverse transcriptional, post-transcriptional and post-translational regulators of MGMT are integrated into a unified control logic, and whether MGMT's non-repair functions are broadly operative, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of regulated MGMT complexes\", \"Cross-regulation among NDRG1, PARP1, HDAC8 and the LINC01956 axis untested\", \"Physiological (non-cancer) role of MGMT regulation undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140097\", \"supporting_discovery_ids\": [0, 24]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 8]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [20]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [0, 1, 8]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 17]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [1, 10]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [13, 16, 14]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"NDRG1\", \"PARP1\", \"ADRM1\", \"DDX46\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":6,"faith_total":6,"faith_pct":100.0}}